Why Aurora Cannabis (TSX:ACB) Stock Price Fell 20% in September

Aurora Cannabis Inc. (TSX:ACB)(NYSE:ACB) stock was pummeled in September after an earnings setback.

| More on:
Cannabis stocks have fallen.
You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

Aurora Cannabis (TSX:ACB)(NYSE:ACB) stock passed through a brutal September. It shed 20% of its value over the course of the month, and has now retreated to a 52-week low. What is behind this pullback? Let’s jump in and find out.

Disappointing earnings and a profitability setback

The company released its fourth-quarter and full-year results for fiscal 2019 in early September. Aurora had previously boasted that it would be able to achieve profitability by the end of the fiscal year. This turned out to be an overreach as Aurora conceded in this earnings release that it will not be able to turn a profit until fiscal 2020.

This comes a month after another top producer, Canopy Growth, reported a revenue miss and pushed back its profitability guidance. Adjusted EBITDA at Aurora came in at a loss of $11.7 million, net revenue rose to $98.9 million, and gross margin was 58%. All fell below estimates in the quarter. Aurora blamed some of its setbacks on the slow pace of retail cannabis roll outs in Canada.

Aurora is now more likely to hit its profit goal by the second quarter of fiscal 2020.

Cash concerns

Cannabis companies are gearing up for big product launches ahead of “Cannabis 2.0”, but Aurora finds itself in a sticky cash position. Aurora has been generating significant cash flow and operating investing losses over the past several quarters. In its most recent quarter, Aurora bled $180.4 million in operating losses and investments.

Aurora’s cash and securities balances sat at just over $200 million at the end of the fourth quarter. The company raised an additional $360 million credit facility early last month. Still, the move drew attention to a troubling issue that is putting even more pressure on Aurora to turn a profit. Canopy Growth, by contrast, boasts over $3 billion in cash.

The company needs to solve its liquidity problem ahead of the next calendar year. It brought on strategist Nelson Peltz in order to broker partnerships, but a breakthrough has yet to be achieved. Until Aurora receives a cash injection, investors have every right to worry about its precarious liquidity position.

Short sellers on the assault

Many of the top cannabis stocks have been reeling since the middle of spring, and this has naturally drawn the attention of short sellers. Analysis by S3 Partners revealed in mid-September that short sellers had raked in USD $1.17 billion so far in the third quarter on pot positions. Short interest in the sector has increased roughly 80% in 2019.

Other sectors have stabilized on the TSX, which has moved short interest to more vulnerable spaces. Top cannabis companies have pushed back profit guidance while maintaining sky-high market valuations. It continues to be a sector ripe for short interest.

Until these fundamental issues are resolved, this will continue to be an issue for Aurora and its peers.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Ambrose O'Callaghan has no position in any of the stocks mentioned.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »